On Tuesday, December 7, a Food and Drug Administration advisory panel voted 13 to 7 to recommend approval for Orexigen Therapeutics (OREX)'s obesity drug Contrave.
Contrave moves closer to commercialization while its two principal rivals -- Arena Pharmaceuticals's (ARNA) Lorquess, or lorcaserin, and Vivus Inc's.(VVUS) Qnexa -- were sent back to the drawing board in October because of safety concerns.
Complete Story »
Kate Mara Izabella Scorupco Carla Campbell Penélope Cruz Kristen Bell
No comments:
Post a Comment